Observation on the Efficacy and Mechanism of SLIT With Dust Mite Allergen for PAR
Status:
Not yet recruiting
Trial end date:
2024-12-30
Target enrollment:
Participant gender:
Summary
Allergic rhinitis is a common and recurrent ear, nose and throat (ENT) disease. It is a
chronic or seasonal condition affecting 10% to 20% of the world's population. It is
considered one of the most difficult diseases to treat globally and has become a major global
health problem.
SUblingual immunotherapy (SIT) is currently considered to be an effective pairings therapy
that can alter the natural progression of allergic rhinitis through immunomodulatory
mechanisms. Immunotherapy is more suitable for patients with moderate to severe intermittent
or persistent allergic rhinitis, especially for those with poor drug treatment. This
treatment can significantly reduce the severity of allergic rhinitis, reduce the use of
allergy medications, and improve the quality of life for many patients.
In the development of allergic rhinitis, the regulation of immune balance in Th1 / Th2 / Th17
cells is currently considered to be an important approach in the treatment of allergic
rhinitis. But a growing body of evidence suggests that an intrinsic immune response is also
the pathogenesis of allergic rhinitis. Innate lymphocytes are involved in mucosal immune
formation, lymphocyte development, tissue damage repair and epithelial barrier protection,
and play an important role in fighting infection, regulating inflammation and maintaining
immune homeostasis. Three subsets of intrinsic lymphocytes (ILC1s, ILC2s, ILC3s) have been
proposed to functionally approximate Th1, Th2, and Th17 in helper T lymphocytes (Th), but the
results are inconclusive and the mechanism of ILCs role in AR progression is not fully
elucidated.
Therefore, the purpose of this study was to investigate the efficacy and mechanism of
subglossal immunotherapy for perennial allergic rhinitis, and to reveal the correlation
between ILCs (ILC1s, ILC2s, ILC3s) and Th1 / Th2 / Th17 cell immunity, and to provide a basis
for clinical studies of allergic rhinitis.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
People's Hospital of Anshun City of Guizhou Province